Following a nod from the US FDA in August, Galderma has received a positive opinion recommending the granting of a marketing authorization of Mirvaso (brimonidine tartrate 3 mg/g gel) from the EU's CHMP, for the symptomatic treatment of facial erythema of rosacea in adult patients.
The product's US arrival swelled Galderma's portfolio of rosacea treatments, which also includes Oracea (doxycycline) and MetroGel (metronidazole) 1% pump (scripintelligence.com, 26 August 2013). This product differs by constricting...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?